Skip to main content

Compare Stocks

Date Range: 

 ADMA BiologicsLogicBio TherapeuticsProtalix BioTherapeuticsGamida CellGenfit
SymbolNASDAQ:ADMANASDAQ:LOGCNYSEAMERICAN:PLXNASDAQ:GMDANASDAQ:GNFT
Price Information
Current Price$1.62$4.43$2.87$6.30$4.11
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.31.31.41.3
Analysis Score3.53.53.53.53.3
Community Score3.02.42.42.72.7
Dividend Score0.00.00.00.00.0
Ownership Score0.80.00.00.00.0
Earnings & Valuation Score0.60.60.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$7.80$18.50$7.00$20.25$51.00
% Upside from Price Target381.48% upside317.61% upside143.90% upside221.43% upside1,140.88% upside
Trade Information
Market Cap$196.47 million$142.47 million$130.25 million$152.59 million$188.14 million
Beta1.841.342.872.031.33
Average Volume6,460,805131,9001,226,719782,690184,713
Sales & Book Value
Annual Revenue$29.35 millionN/A$54.69 millionN/A$45.88 million
Price / Sales6.69N/A2.38N/A4.10
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.44 per share$1.84 per share($4.74) per share$1.44 per share$2.49 per share
Price / Book3.68N/A-0.61N/A1.65
Profitability
Net Income$-48,280,000.00$-40,130,000.00$-18,280,000.00$-34,350,000.00$-72,960,000.00
EPS($0.92)($1.78)($1.23)($1.69)($1.97)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/A287.00N/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-166.01%N/A-10.84%N/AN/A
Return on Equity (ROE)-98.83%-117.64%N/A-112.47%N/A
Return on Assets (ROA)-37.21%-76.85%-9.74%-65.09%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio1.40%0.40%N/AN/A5.74%
Current Ratio8.47%6.21%1.37%5.39%5.71%
Quick Ratio4.24%6.21%1.07%5.39%5.71%
Ownership Information
Institutional Ownership Percentage48.90%33.78%14.28%N/A0.41%
Insider Ownership Percentage11.70%23.40%1.64%N/AN/A
Miscellaneous
Employees40639207110203
Shares Outstanding121.28 million32.16 million45.38 million24.22 million45.78 million
Next Earnings Date8/4/2021 (Estimated)8/9/2021 (Estimated)5/14/2021 (Confirmed)8/10/2021 (Estimated)7/1/2021 (Estimated)
OptionableOptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
Nash Market to Witness Huge Growth by 2028 | Novo Nordisk, Galmed Pharmaceuticals, Genfit Intercept, Galectin Therapeutics and Gilead Sciences. – Clark County Blog - Clark County BlogNash Market to Witness Huge Growth by 2028 | Novo Nordisk, Galmed Pharmaceuticals, Genfit Intercept, Galectin Therapeutics and Gilead Sciences. – Clark County Blog - Clark County Blog
clarkcountyblog.com - May 13 at 10:53 AM
Ninety One UK Ltd - Form 8.3 - Gamesys Group Plc - Yahoo Finance UKNinety One UK Ltd - Form 8.3 - Gamesys Group Plc - Yahoo Finance UK
uk.finance.yahoo.com - May 12 at 11:37 PM
The Diverse Income Trust Plc - Redemption of Ordinary Shares - Yahoo Finance UKThe Diverse Income Trust Plc - Redemption of Ordinary Shares - Yahoo Finance UK
uk.finance.yahoo.com - May 12 at 6:37 PM
Genfits Post-NASH Plans Center On ACLF, Cholestatic Liver Disease - ScripGenfit's Post-NASH Plans Center On ACLF, Cholestatic Liver Disease - Scrip
scrip.pharmaintelligence.informa.com - May 12 at 6:37 PM
Genfit SA Stock Shows Every Sign Of Being Possible Value Trap - Yahoo FinanceGenfit SA Stock Shows Every Sign Of Being Possible Value Trap - Yahoo Finance
finance.yahoo.com - May 12 at 6:37 PM
GENFIT: Reports First Quarter 2021 Financial Information - GlobeNewswireGENFIT: Reports First Quarter 2021 Financial Information - GlobeNewswire
globenewswire.com - May 12 at 6:37 PM
Genfit SA Stock Shows Every Sign Of Being Possible Value Trap - GuruFocus.comGenfit SA Stock Shows Every Sign Of Being Possible Value Trap - GuruFocus.com
gurufocus.com - May 12 at 1:37 PM
Non-Alcoholics Steatohepatitis Market 2021 Industry Analysis, Trends, and Forecast : Genfit, Gilead Sciences, 1Galectin Therapeutics, Galmed Pharmaceuticals – Clark County Blog - Clark County BlogNon-Alcoholics Steatohepatitis Market 2021 Industry Analysis, Trends, and Forecast : Genfit, Gilead Sciences, 1Galectin Therapeutics, Galmed Pharmaceuticals – Clark County Blog - Clark County Blog
clarkcountyblog.com - May 11 at 8:08 PM
GENFIT Provides Pipeline Update and Launch of New Clinical - GlobeNewswireGENFIT Provides Pipeline Update and Launch of New Clinical - GlobeNewswire
globenewswire.com - May 11 at 8:08 PM
Obeticholic Acid Market 2021 Overview, Industry by Type, by Manufacturers : Genfit SA, Intercept Pharmaceuticals, Inc., Galmed Pharmaceuticals Ltd., Tobira Therapeutics, Inc. – Test & Measurement - Test & MeasurementObeticholic Acid Market 2021 Overview, Industry by Type, by Manufacturers : Genfit SA, Intercept Pharmaceuticals, Inc., Galmed Pharmaceuticals Ltd., Tobira Therapeutics, Inc. – Test & Measurement - Test & Measurement
testmeasurement.com.au - May 11 at 10:04 AM
GENFIT Annual Combined General Meeting of June 15, 2021 - - GlobeNewswireGENFIT Annual Combined General Meeting of June 15, 2021 - - GlobeNewswire
globenewswire.com - May 10 at 7:26 PM
Nonalcoholic Steatohepatitis (NASH) Market Analysis, Revenue, Price, Market Share, Growth Rate, Forecast To 2025 – BeverageManager .Net - BeverageManager .NetNonalcoholic Steatohepatitis (NASH) Market Analysis, Revenue, Price, Market Share, Growth Rate, Forecast To 2025 – BeverageManager .Net - BeverageManager .Net
beveragemanager.net - May 10 at 9:23 AM
Nuclear Receptor ROR Gamma Market Overview, Growth Rate and Future Scenario 2027| Genfit SA, GlaxoSmithKline Plc, Aurigene Discovery Technologies – BeverageManager .Net - BeverageManager .NetNuclear Receptor ROR Gamma Market Overview, Growth Rate and Future Scenario 2027| Genfit SA, GlaxoSmithKline Plc, Aurigene Discovery Technologies – BeverageManager .Net - BeverageManager .Net
beveragemanager.net - May 9 at 7:59 AM
Nash Market Research Report, Growth Trends and Competitive Analysis 2021-2027 | Novo Nordisk, Galmed Pharmaceuticals, Genfit Intercept, Galectin Therapeutics and Gilead Sciences. – BeverageManager .Net - BeverageManager .NetNash Market Research Report, Growth Trends and Competitive Analysis 2021-2027 | Novo Nordisk, Galmed Pharmaceuticals, Genfit Intercept, Galectin Therapeutics and Gilead Sciences. – BeverageManager .Net - BeverageManager .Net
beveragemanager.net - May 8 at 7:55 PM
Increasing Demand of Nonalcoholic Steatohepatitis (Nash) Market by 2027 | GENFIT SA, Viking Therapeutics, Tobira Therapeutics, Inc. – Clark County Blog - Clark County BlogIncreasing Demand of Nonalcoholic Steatohepatitis (Nash) Market by 2027 | GENFIT SA, Viking Therapeutics, Tobira Therapeutics, Inc. – Clark County Blog - Clark County Blog
clarkcountyblog.com - May 7 at 8:22 AM
Global Non-Alcoholic Steatohepatitis Management Market 2021:Sets the Table for Continued Growth||Key Players-Galmed Pharmaceuticals Ltd, Gemphire Therapeutics, Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc - The Manomet CurrentGlobal Non-Alcoholic Steatohepatitis Management Market 2021:Sets the Table for Continued Growth||Key Players-Galmed Pharmaceuticals Ltd, Gemphire Therapeutics, Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc - The Manomet Current
manometcurrent.com - May 6 at 8:40 AM
Global Roundup: GENFIT Launches NASH Diagnostic Kit in US, Canada | BioSpace - BioSpaceGlobal Roundup: GENFIT Launches NASH Diagnostic Kit in US, Canada | BioSpace - BioSpace
biospace.com - May 5 at 5:38 PM
Insights on the Non-Alcoholic Steatohepatitis (NASH) Biomarker Global Market to 2028 - by Type, Industry Verticals and Region - Yahoo FinanceInsights on the Non-Alcoholic Steatohepatitis (NASH) Biomarker Global Market to 2028 - by Type, Industry Verticals and Region - Yahoo Finance
finance.yahoo.com - May 5 at 7:38 AM
Peroxisome Proliferator Activated Receptor Delta Market to Witness Robust Expansion by 2026 | Chipscreen Biosciences Ltd, Connexios Life Sciences Pvt Ltd, CymaBay Therapeutics Inc, Genfit SA, Inventiva, Mitobridge Inc - Clark County BlogPeroxisome Proliferator Activated Receptor Delta Market to Witness Robust Expansion by 2026 | Chipscreen Biosciences Ltd, Connexios Life Sciences Pvt Ltd, CymaBay Therapeutics Inc, Genfit SA, Inventiva, Mitobridge Inc - Clark County Blog
clarkcountyblog.com - May 3 at 11:24 PM
Francisco Partners, TPG buy Dells cloud business Boomi for $4 billion - Yahoo Finance UKFrancisco Partners, TPG buy Dell's cloud business Boomi for $4 billion - Yahoo Finance UK
uk.finance.yahoo.com - May 3 at 8:23 AM
GENFIT announces the launch by Labcorp of NASHnext® A Novel - GlobeNewswireGENFIT announces the launch by Labcorp of NASHnext® A Novel - GlobeNewswire
globenewswire.com - May 3 at 8:23 AM
Short Interest in Genfit SA (NASDAQ:GNFT) Grows By 48.9%Short Interest in Genfit SA (NASDAQ:GNFT) Grows By 48.9%
americanbankingnews.com - May 1 at 10:00 AM
Nuclear Receptor ROR Gamma Market Size, Status, Global Demands and Top Manufacturers 2021 | Genfit SA, GlaxoSmithKline Plc, Aurigene Discovery Technologies, Beijing Hanmi Pharmaceutical, Biogen Inc, AbbVie Inc - Clark County BlogNuclear Receptor ROR Gamma Market Size, Status, Global Demands and Top Manufacturers 2021 | Genfit SA, GlaxoSmithKline Plc, Aurigene Discovery Technologies, Beijing Hanmi Pharmaceutical, Biogen Inc, AbbVie Inc - Clark County Blog
clarkcountyblog.com - April 30 at 7:44 PM
Cardiometabolic Drug Market Size 2021 Global Business Trends, Modest Analysis, Statistics, Forecast 2021-2025 | Prudent Markets - Clark County BlogCardiometabolic Drug Market Size 2021 Global Business Trends, Modest Analysis, Statistics, Forecast 2021-2025 | Prudent Markets - Clark County Blog
clarkcountyblog.com - April 29 at 7:41 PM
Nash Drugs Market (Covid-19 Analysis) SWOT Analysis, Key Indicators, Forecast 2028 | Galmed Pharmaceuticals, Genfit SA, Intercept Pharmaceuticals, Inc., Conatus Pharmaceuticals - Jumbo NewsNash Drugs Market (Covid-19 Analysis) SWOT Analysis, Key Indicators, Forecast 2028 | Galmed Pharmaceuticals, Genfit SA, Intercept Pharmaceuticals, Inc., Conatus Pharmaceuticals - Jumbo News
jumbonews.co.uk - April 29 at 7:41 PM
DateCompanyBrokerageAction
4/5/2021ADMA BiologicsJefferies Financial GroupReiterated Rating
4/1/2021ADMA BiologicsRaymond JamesLower Price Target
3/26/2021ADMA BiologicsMaxim GroupReiterated Rating
1/4/2021ADMA BiologicsHC WainwrightLower Price Target
8/6/2020ADMA BiologicsOppenheimerInitiated Coverage
8/12/2019ADMA BiologicsDawson JamesDowngrade
4/4/2019ADMA BiologicsWBB SecuritiesUpgrade
3/10/2021LogicBio TherapeuticsJMP SecuritiesInitiated Coverage
3/1/2021LogicBio TherapeuticsWilliam BlairReiterated Rating
5/22/2020LogicBio TherapeuticsChardan CapitalReiterated Rating
5/1/2019LogicBio TherapeuticsRoth CapitalInitiated Coverage
11/13/2018LogicBio TherapeuticsBarclaysInitiated Coverage
3/15/2021Gamida CellNeedham & Company LLCLower Price Target
3/9/2021Gamida CellPiper SandlerLower Price Target
6/30/2020Gamida CellEvercore ISIInitiated Coverage
2/26/2020Gamida CellBMO Capital MarketsLower Price Target
11/21/2018Gamida CellCIBCInitiated Coverage
4/5/2021GenfitSVB LeerinkLower Price Target
2/12/2021GenfitBryan, Garnier & CoUpgrade
7/23/2020GenfitStifel NicolausUpgrade
6/25/2020GenfitBank of AmericaInitiated Coverage
5/22/2020GenfitB. RileyBoost Price Target
5/13/2020GenfitKepler Capital MarketsDowngrade
5/12/2020GenfitOddo BhfDowngrade
(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.